^
    Back
    Association details:
    Biomarker:GLI1 expression
    Cancer:Non Small Cell Lung Cancer
    Drug:erlotinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Oncol Lett
    Title:

    GLI1 activation is a key mechanism of erlotinib resistance in human non-small cell lung cancer

    Published date:
    07/31/2020
    Excerpt:
    GLI1 mRNA expression levels were found to be positively correlated with the IC50 of erlotinib in 15 non-small cell lung cancer (NSCLC) cell lines. The downregulation of GLI1 using siRNA sensitized lung cancer cells to the erlotinib treatment, whereas the overexpression of GLI1 increased the survival of lung cancer cells in the presence of erlotinib...
    DOI:
    10.3892/ol.2020.11937